Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis

Table 1

Inflammatory markers.

Markers	Healthy; controls	MS patients
		Baseline treatment		Natalizumab
				3 months			6 months
MMP-9	636.3 (349.9)	565.7 (280.7)	0.613	474.7 (214.1)	0.205	0.446	467.2 (209.2)	0.385
Neopterin	5.7 (1.4)	9.6 (4.8)	0.029	6.6 (1.4)	0.144	0.033	6.0 (0.5)	0.018
Osteopontin	51.1 (18)	104.1 (40.6)	0.002	81 (24.5)	0.006	0.073	84.2 (29.1)	0.225

Values shown are mean (± SD) ng/mL.
—comparison between patients at baseline and healthy controls.
—comparison between patients at three months on Natalizumab therapy and healthy controls.
—comparison between patients at baseline and at three months on Natalizumab therapy.
—comparison between patients at baseline and at six months of Natalizumab therapy.